Brovana
Total Payments
$41,158
Transactions
83
Doctors
29
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $457.67 | 30 | 27 |
| 2018 | $40,701 | 53 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $40,616 | 50 | 98.7% |
| Food and Beverage | $457.67 | 30 | 1.1% |
| Education | $84.40 | 3 | 0.2% |
Payments by Type
Research
$40,616
50 transactions
General
$542.07
33 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects | Sunovion Pharmaceuticals Inc. | $40,616 | 0 |
Top Doctors Receiving Payments for Brovana — Page 2
Ad
Manufacturing Companies
- Sunovion Pharmaceuticals Inc. $41,158
Product Information
- Type Drug
- Total Payments $41,158
- Total Doctors 29
- Transactions 83
About Brovana
Brovana is a drug associated with $41,158 in payments to 29 healthcare providers, recorded across 83 transactions in the CMS Open Payments database. The primary manufacturer is Sunovion Pharmaceuticals Inc..
Payment data is available from 2018 to 2019. In 2019, $457.67 was paid across 30 transactions to 27 doctors.
The most common payment nature for Brovana is "Unspecified" ($40,616, 98.7% of total).
Brovana is associated with 1 research study, including "A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects" ($40,616).